{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that LRRK2 mutations, including G2019S, are associated with Parkinson disease (PD) through increased kinase activity leading to neurotoxicity, causing selective loss of dopaminergic (DA) neurons.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined as increased kinase activity of LRRK2 leading to neurotoxicity and DA neuronal loss, which is relevant to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses transgenic Drosophila models over-expressing human LRRK2 G2019S to assess DA neuronal loss, locomotion deficits, and sensitivity to rotenone, reflecting PD-related phenotypes.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (transgenic fly model assessing neuronal degeneration and locomotion) effectively models PD pathogenesis by mimicking DA neuronal loss and related phenotypes.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper includes wild-type LRRK2 as a negative control and multiple mutant variants as positive controls. Experiments such as climbing assays were performed in triplicate (three trials per experiment), and DA neuron counts were quantified across multiple flies (n=10-15).",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type LRRK2) and abnormal (mutant LRRK2 variants) controls are used, and replicates are explicitly mentioned for key experiments, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study uses multiple LRRK2 variants (G2019S, Y1699C, G2385R) known to be pathogenic or risk alleles in PD as controls for comparison, alongside wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (G2019S, Y1699C) are used as controls in the assays, satisfying the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance for quantitative data (e.g., DA neuron counts, climbing scores) was analyzed using Student's t-test with p-values reported (*p < 0.05, **p < 0.001).",
          "judgment": "No",
          "reasoning": "While statistical tests are performed, there is no direct calculation or estimation of OddsPath or equivalent quantitative measure of pathogenicity likelihood specific to functional data for G2019S.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes at least three variant controls (G2019S, Y1699C, G2385R) identified as pathogenic or risk alleles across the assays.",
          "judgment": "Less than 11",
          "reasoning": "The total number of benign/pathogenic variant controls used is less than 11, as only a few specific variants are tested.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S is rated as PS3_supporting due to the use of a relevant transgenic Drosophila model demonstrating DA neuronal loss and locomotion deficits, with appropriate controls and replicates. However, the lack of OddsPath calculation and limited number of variant controls restricts the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations, including Y1699C, are linked to Parkinson disease through mechanisms involving neurotoxicity and loss of dopaminergic (DA) neurons, often tied to altered kinase activity.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is defined as LRRK2 mutation-induced neurotoxicity leading to DA neuronal loss, relevant to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transgenic Drosophila over-expressing human LRRK2 Y1699C were used to evaluate DA neuronal degeneration and locomotion deficits, mirroring PD phenotypes.",
          "judgment": "Yes",
          "reasoning": "The assay class (transgenic fly model) is applicable as it models PD-relevant outcomes like DA neuronal loss and locomotion impairment.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 serves as a negative control, and multiple mutant variants as positive controls. Replicates are mentioned for climbing assays (three trials) and DA neuron counts (n=10-15).",
          "judgment": "Yes",
          "reasoning": "Both normal and abnormal controls are included, and replicates are documented, fulfilling the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study includes multiple known pathogenic LRRK2 variants (G2019S, Y1699C, G2385R) as controls for comparison.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants are used as controls, meeting the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis using Student's t-test is reported for quantitative data (*p < 0.05, **p < 0.001), but no OddsPath or equivalent is calculated.",
          "judgment": "No",
          "reasoning": "Statistical tests are present, but there is no specific OddsPath calculation or direct quantitative pathogenicity measure for Y1699C.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "At least three variant controls (G2019S, Y1699C, G2385R) are used in the study as pathogenic or risk alleles.",
          "judgment": "Less than 11",
          "reasoning": "The total number of variant controls is less than 11, limiting the evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "LRRK2 Y1699C receives a PS3_supporting rating for functional evidence due to demonstrated DA neuronal loss in a relevant fly model with adequate controls and replicates. The strength is limited to supporting due to the absence of OddsPath calculation and a small number of variant controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": "2385"
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper describes LRRK2 G2385R as a risk allele for PD in Asian populations, associated with neurotoxicity and DA neuronal loss, though possibly through activity-independent mechanisms.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is defined as neurotoxicity leading to DA neuronal loss, relevant to PD, even if the exact mechanism for G2385R differs from kinase activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transgenic Drosophila over-expressing LRRK2 G2385R were assessed for DA neuronal degeneration and rotenone sensitivity, relevant to PD phenotypes.",
          "judgment": "Yes",
          "reasoning": "The transgenic fly model is applicable as it evaluates PD-relevant outcomes such as DA neuronal loss and environmental toxin sensitivity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 is used as a negative control, and mutant variants as positive controls. Replicates are noted for climbing assays (three trials) and DA neuron counts (n=10-15).",
          "judgment": "Yes",
          "reasoning": "Both types of controls are present, and replicates are documented, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic LRRK2 variants (G2019S, Y1699C) and the risk allele G2385R are used as controls in the study.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants are included as controls, satisfying the variant control requirement.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance is assessed using Student's t-test (*p < 0.05, **p < 0.001), but no OddsPath or equivalent measure is provided.",
          "judgment": "No",
          "reasoning": "While statistical analysis is performed, there is no direct OddsPath calculation or specific pathogenicity likelihood measure for G2385R.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses at least three variant controls (G2019S, Y1699C, G2385R) identified as pathogenic or risk alleles.",
          "judgment": "Less than 11",
          "reasoning": "The total number of variant controls is less than 11, which limits the evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2385R is rated as PS3_supporting based on observed DA neuronal loss and rotenone sensitivity in a relevant fly model with proper controls and replicates. The strength remains supporting due to the lack of OddsPath calculation and limited variant controls."
    }
  ]
}